Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

69
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
69
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

57
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
57
Truncation in Survival Analysis01:09

Truncation in Survival Analysis

129
Truncation in survival analysis refers to the exclusion of individuals or events from the dataset based on specific criteria related to the time of the event. This exclusion can happen in two primary forms: left truncation and right truncation.
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are...
129
Decision Making: P-value Method01:09

Decision Making: P-value Method

5.2K
The process of hypothesis testing based on the P-value method includes calculating the P- value using the sample data and interpreting it.
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim  is also stated. These statements can act as null and alternative hypotheses:  a null hypothesis would be a neutral statement while the alternative hypothesis can...
5.2K
Friedman Two-way Analysis of Variance by Ranks01:21

Friedman Two-way Analysis of Variance by Ranks

99
Friedman's Two-Way Analysis of Variance by Ranks is a nonparametric test designed to identify differences across multiple test attempts when traditional assumptions of normality and equal variances do not apply. Unlike conventional ANOVA, which requires normally distributed data with equal variances, Friedman's test is ideal for ordinal or non-normally distributed data, making it particularly useful for analyzing dependent samples, such as matched subjects over time or repeated measures...
99
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

90
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
90

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study.

Neurology(R) neuroimmunology & neuroinflammation·2025
Same author

From Data to Knowledge. Advancing Life Sciences: Editorial for the CEN2023 Special Issue.

Biometrical journal. Biometrische Zeitschrift·2025
Same author

AI-driven reclassification of multiple sclerosis progression.

Nature medicine·2025
Same author

Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study.

Neurology(R) neuroimmunology & neuroinflammation·2025
Same author

Performance of Composite Endpoints Defining Progression Independent of Relapse Activity in Multiple Sclerosis.

Annals of clinical and translational neurology·2025
Same author

Analysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims data.

Multiple sclerosis and related disorders·2025
Same journal

Understanding the Added Value of Action Limits for QTL Monitoring.

Therapeutic innovation & regulatory science·2026
Same journal

Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?

Therapeutic innovation & regulatory science·2026
Same journal

Validation of the Ontario Protocol Assessment Level (OPAL) Tool for Assessing Clinical Trial Complexity and Supporting Workforce Planning in the Italian Clinical Research Context.

Therapeutic innovation & regulatory science·2026
Same journal

The Effect of Covariate Adjustment for Cox Regression in Cardiovascular Outcome Trials.

Therapeutic innovation & regulatory science·2026
Same journal

Current Status and Construction Requirements of Drug Clinical Trial Institutions in Sichuan Province in China.

Therapeutic innovation & regulatory science·2026
Same journal

The CARE Program: An Initiative of Patient-Focused Drug Development for Rare Diseases by NMPA.

Therapeutic innovation & regulatory science·2026
See all related articles

Related Experiment Video

Updated: May 13, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.3K

Futility Interim Analyses - A Plea for Simplicity.

Gian-Andrea Thanei1, Gaëlle Klingelschmitt2, Claude Berge2

  • 1Product Development Data Sciences, Pharma Development, Roche, Basel, Switzerland. gian-andrea.thanei@roche.com.

Therapeutic Innovation & Regulatory Science
|April 14, 2025
PubMed
Summary
This summary is machine-generated.

Futility interim analyses can reduce drug development risks affordably but are underused due to fear of premature termination. This study offers a simple strategy to better understand and manage futility risks in clinical trials.

Keywords:
Clinical drug developmentFutility interim analysisFutility riskOperating characteristicsRetrospective futility analysis

More Related Videos

High-Throughput Screening of Microbial Isolates with Impact on Caenorhabditis elegans Health
11:40

High-Throughput Screening of Microbial Isolates with Impact on Caenorhabditis elegans Health

Published on: April 28, 2022

2.6K
Observational Study Protocol for Repeated Clinical Examination and Critical Care Ultrasonography Within the Simple Intensive Care Studies
10:38

Observational Study Protocol for Repeated Clinical Examination and Critical Care Ultrasonography Within the Simple Intensive Care Studies

Published on: January 16, 2019

20.1K

Related Experiment Videos

Last Updated: May 13, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.3K
High-Throughput Screening of Microbial Isolates with Impact on Caenorhabditis elegans Health
11:40

High-Throughput Screening of Microbial Isolates with Impact on Caenorhabditis elegans Health

Published on: April 28, 2022

2.6K
Observational Study Protocol for Repeated Clinical Examination and Critical Care Ultrasonography Within the Simple Intensive Care Studies
10:38

Observational Study Protocol for Repeated Clinical Examination and Critical Care Ultrasonography Within the Simple Intensive Care Studies

Published on: January 16, 2019

20.1K

Area of Science:

  • Clinical Drug Development
  • Biostatistics
  • Pharmaceutical Research

Background:

  • Futility interim analyses are crucial for risk management in innovative therapy development.
  • These analyses are underutilized due to team apprehension about potentially terminating successful treatments.
  • Current planning often involves complex statistical modeling, hindering accessibility.

Purpose of the Study:

  • To propose a straightforward strategy for establishing futility thresholds in clinical trials.
  • To introduce an intuitive measure for evaluating futility risks.
  • To simplify the understanding and application of futility analyses in drug development.

Main Methods:

  • Development of a simple strategy for defining the range of futility thresholds.
  • Introduction of a novel, intuitive futility risk measure.
  • Focus on clear communication and risk assessment for development teams.

Main Results:

  • A simplified approach to setting futility thresholds is presented.
  • An intuitive risk measure aids in evaluating the likelihood of futility.
  • The proposed methods aim to demystify futility analyses for development teams.

Conclusions:

  • Overestimated risks associated with futility interim analyses can be mitigated.
  • A straightforward strategy and intuitive measure can improve the adoption and understanding of futility analyses.
  • Enhanced communication and simplified tools can empower clinical development teams to utilize futility analyses more effectively.